Valeant Tumbles on Earnings Woes

Valeant Pharmaceuticals (VRX) was plummeting in morning trading Tuesday, with more than a quarter of the debt-laden drugmaker's market cap vanishing before the opening bell on a disastrous earnings rollout.

Shares of Valeant were down more than 20% at $14.95 a share in early trading after the struggling Canadian drugmaker posted third-quarter earnings far below consensus estimates, compounded by cuts to its guidance for the remainder of the year -- putting Valeant at risk of breaching covenants on some of its roughly $31 billion of debt.

Earnings clocked in at $1.55 a share for the third quarter, below average analyst expectations of $1.76, while sales of $2.48 billion for the period fell short of the $2.52 billion predicted. Valeant also slashed its earnings guidance to a range of $5.30 to $5.50 a share for the year, from a previous range of $6.60 to $7.

"We can't change the things in the past; we can only deal with them and change our future," Valeant's newly appointed CFO Paul Herendeen said on Tuesday morning's earnings call with analysts. "We are a new team, and we need to earn your trust. We will do that by being a good corporate citizen, by delivering on our commitments and by being transparent in our financial reporting."

Valeant stock fell by more than 25% at one point in premarket trading, although it recovered somewhat once the market actually opened. But all told, Valeant shares are down about 86% so far this year amid controversy surrounding alleged accounting problems and steep price hikes on products the firm acquired during years of debt-fueled acquisitions. The scandals led to the departure of Chairman and CEO J. Michael Pearson and CFO Howard Schiller from Valeant, which is a member of our "Stressed Out" list of stocks that face big debt pressures.

Valeant has previously admitted to roughly $58 million of improperly booked sales tied to its former partnership with mail-order pharmacy Philidor. Last fall, reports of alleged accounting misconduct involving Philidor ignited congressional and U.S. Securities and Exchange Commission investigations and led to a delay in Valeant's annual and first-quarter SEC filings. Those delays in turn put Valeant in apparent violation of its bond indentures and loan covenants, prompting a fight with creditors which hold Valeant's $31 billion of debt.

Employees of TheStreet are restricted from trading individual securities.

More from Stocks

12 Stocks That Make Up the GLUM Index

12 Stocks That Make Up the GLUM Index

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Worth a Stunning $6.6 Trillion, Tech Stocks Have Taken Over the Market

Worth a Stunning $6.6 Trillion, Tech Stocks Have Taken Over the Market

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Here's Why Snap Shares Climbed Monday

Here's Why Snap Shares Climbed Monday